 |  |  |  |  |  |  |  |
Eric is one of the company’s founders. He is the current CEO of the company. His leadership has successfully brought the company from the drug discovery phase to the current clinical development phases. Eric has a demonstrated track record as a biotech entrepreneur, having successfully overseen and led the development of several Biotech start-up ventures. He is currently an Advisor and Board Member of various biotech companies in Europe. Eric began his career in the Pharmaceuticals Industry and then later moved to Medical Devices. He has held Senior Management positions in the field of sales & marketing, licensing, strategic alliances and R&D. He also has extensive experience in the regulatory & reimbursement fields. Eric holds a Master in Psychology from the University of Bordeaux (France).
Salman is the company’s principal founder and an established scientific leader whose early ground breaking work in angiogenesis earned him well recognized honours and awards from the French Government. Salman has successfully led Gene Signal’s discovery team and his work has allowed the company to become owner of one of the world’s largest collection of patents in the field of angiogenesis. Prior to Gene Signal Salman led several scientific teams in the field of angiogenesis, oncology and cell-signalling. He was a scientist and Head of the Biochemistry team in the NADER oncology laboratory at Cochin Hospital, Paris and Head of the Radioactive Labeling team at the Center for Nuclear Medicine, Faculty of Medicine, University of Nancy. Salman holds a PhD in Microbial Biochemistry from the University of Nancy (France), a Master of Science in Applied Biology for Nutrition and BioIndustry from the University of Nancy, France.
Eric is one of the company’s founders. Eric directs the Company’s drug development work and has successfully steered Gene Signal’s leading products through several drug development phases. Eric is a recognized international expert in the field of vascular mechanisms and CVD. He is Associate Professor of Surgery of the Faculty of Medicine of the University of Montreal and a senior researcher at the Montreal Heart Institute. He was formerly Head of Cardiovascular Pharmacology of Actelion Pharmaceuticals (Basel, Switzerland). Eric has received the 1996 Young Investigator Award from the International Society of Hypertension, the 1997 Jonathan Ballon Award of the Quebec Heart & Stroke Foundation and the 1999 MacDonald Award of the Canadian Heart & Stroke Foundation.
Georges is currently CEO of a company listed on the European Stock Exchange. He is one of the most respected and talented person in the private Pharmaceutical Industry and has a very wide network in this field in France as well as in Canada. His experience will be a considerable strength for Gene Signal in the future.
Jean Pierre brings more than 20 years of solid experience in general management and business development. He has a solid track- record as an entrepreneur and has successfully founded and developed several start-up operations all over the world. His leadership and management skills have driven long-term growth and profitability and have enabled the successful development of several energy groups.
